• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Relpax (eletriptan hydrobromide) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – July 2010

 

Summary View

WARNINGS

Postmarketing experience with eletriptan: Serious cardiovascular events, some resulting in death, have been reported in association with the use of Relpax.

ADVERSE REACTIONS

Other Events Observed During Post-Marketing Use
  • Neurological: seizure